Appendix 4 - extensive overview of existing studies that touch some aspects of BeLOVE

Important recent Acute Heart Failure (AHF) cohorts

Name	Main Objective	Status	Study type	n & observation period	Participant characteristics	Main Outcome	Acute Phenotyping	Follow up
ADHERE Core III - Acute Decompensated Heart Failure Registry [1,2] NCT00366639	to compile a clinical database on the strategy for the medical management of patients hospitalized with acute Heart Failure (HF).	Completed (Oct 2001 – Oct 2006)	multi-center (USA) prospective observational cohort (registry)	n=24118 no scheduled follow up	adults hospitalized for AHF	Acute clinical course	Clinical data and history	none
French Observatory of Acute Heart Failure (OFICA) [3] NCT01080937	to study the changing characteristics of patients and practices in the "real world" and their impact on the prognosis of patients admitted for acute heart failure	Completed (March 2009- Feb 2011)	multi-center (France) prospective observational cohort	n= 1818 3 months	adults hospitalized for AHF	Acute and 3 month clinical course	Clinical data and history	<u>3 month (telephone)</u> Clinical outcome
Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study [4]	to know more about of the epidemiology of acute decompensated heart failure (ADHF) in patients admitted to intensive and coronary care units (ICU/CCU)	Completed (April 2011-April 2011)	multi-center (France) prospective observational cohort	n= 599 1 year	Adults admitted to an ICU or CCU with signs and or symptoms of AHF	Mortality at 1 month and 1 year	Clinical data and history	<u>4 weeks & 1 year</u> Survival
European Society of Cardiology Heart Failure Pilot and Long-Term Registry (ESC-HF-LT) [5, 7, 13]	to describe clinical epidemiology and 1-year outcomes of outpatients and inpatients with heart failure (HF)	Completed (Oct 2009- March 2010)	multi-center, international (12 European countries)) prospective observational cohort	n= 5118 1 year	Adult outpatients with chronic HF (63%) and inpatients admitted for AHF (37%)	All-cause-mortali ty at 1 year	Clinical data and History	<u>1 year</u> All-cause mortality Hospitalization rate
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure	to assess patient characteristics, aetiology, treatment, and outcome of acute	Completed (Oct 2004 – Aug 2005)	multi-center international (30 European countries)	n= 3580 no scheduled Follow up	Adults hospitalized with AHF	Acute clinical course	AHF-classification according to ESC guidelines	none

patients: description of population. [6]	heart failure (AHF) in Europe in relation to the guidelines on the diagnosis and treatment of AHF published by the ESC		prospective observational cohort				Clinical data and history	
Care Pathways of Acute Heart Failure Patients: Impact on In-hospital Mortality. A French National Prospective Survey [8] NCT03903198	to describe the different pre-hospital and in-hospital pathways of patients with acute heart failure (AHF) and their association with in-hospital mortality	Completed (June 2014- Oct 2018)	multi-center (France) prospective observational cohort	n= 3677 no details on FU period per participant given	Adults hospitalized with AHF	Association between hospitalization in cardiology and in-hospital mortality	Clinical data and history	"first recourse" (no further details given)
Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study) (DECIDE) [9] NCT00911703	to determine if certain findings (blood tests, symptom improvement, etc.) after acute heart failure treatment can identify a group of patients who are safe for early hospital discharge	Completed (Aug 2008-Oct 2015)	multi-center (USA) prospective observational cohort	n= 835 1 month	Adults with previously documented EF > 50% who present to and ER with AHF	Heart –failure related adverse events	Clinical data (within 1 hour of initial ER therapy)	<u>5 days and 1 month</u> Adverse events
Permanent Observatory of Heart Failure (ODIN) [10] NCT01091441	(not specified by authors, presumably:) to evaluate the effect of a national education program (I-CARE) for patients with heart failure on 2 year mortality and morbidity	Completed (Feb 2007-July 2014)	multi-center (France) prospective observational cohort	n= 3248 2 years	pts. with HF cared for in centers participating in I-CARE; pts are attributed to a group that did vs. a group that did not receive education	Event-free survival (all cause death)	not specified	Periodic, up to 2 years All-cause mortality Recurrence of heart failure Therapy Number of pts with adverse events
Heart Failure Optimization Study (HF-Opt) [11] NCT03016754	to test the hypothesis that in pts with newly diagnosed HF and prescribed wearable cardioverter defibrillator use additional Ejection Fraction (EF) recovery	Recruiting (Mar 2017 – Jan 2020)	multi-center (30-60 sites, USA and Europe) prospective observational cohort	n= 750 1 year	Adults who were prescribed a wearable cardioverter-defi brillator (WCD) ≤ 10 days post-discharge after	at 6 months: ending WCD use without need for ICD (EF improved, negligible SCD risk) vs.	not specified	Day 30 (pre study) Early clinical outcome <u>6 month</u> Primary outcome measures + incidence of other arrhythmias, number of ICD

	occurs between 90 and 180 days as Guideline Directed Medical Therapy (GDMT) is achieved				hospitalization for a primary reason of new onset HF (≤30 days since first HF hospitalization), with ischemic or non-ischemic cardiomyopathy, and have used the WCD for no more than 30 (part 1) or 90 days (part 2) AND who had an EF ≤ 35%	continue WCD (EF improved, but continued SCD risk)vs. meeting GDMT (EF not improved and continued SCD risk)		schocks + WCD efficacy in ventricular arrhythmia <u>1 year</u> mortality + healthcare costs+ complications from extended GCD use
Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry [12]	to assess patient characteristics, etiology, treatment and outcome of AHF	not specified (recruiting from Sep 2006 to Oct 2009)	multi-center (Czech Republic) prospective observational cohort	n= 4153	Adults hospitalized with AHF	Mortality, clinical course	Clinical data and History	<u>"long term" (not</u> <u>specified)</u> mortality
Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort (Global ResEArch on acute conditions Team, GREAT network) [14]	to assess, according to age groups, patients' characteristics according to region of origin, the chronic therapeutic management, prognostic utility of clinical variables, and natriuretic peptides	Recruiting	multi-center, international (USA, Europe) prospective observational cohort	n= 14758 1 year	Adults attending an ER with AHF	Clinical course Association of e.g. elevated blood glucose [16] and body mass index [17] with mortality	Clinical data and History	<u>30 days + 1 year</u> mortality rate
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial [15]	to determine the influence of different older age groups on baseline characteristics and outcomes in the participants of the randomized controlled	Completed	prospective; RCT (report of observations on the course of participants in the PROTECT trial)	n= 2033 1 year	Adults hospitalized with AHF and known history of HF requiring diuretic treatment; pts. were randomized to i.v. therapy	Mortality and rehospitalization with respect to participants age (primary endpoint of the original RCT was	Clinical data and History	7 & 30 days mortality cardiovascular or renal hospitalization <u>1 year</u>

	PROTECT trial (median age 72yrs)				with rolofyline vs. placebo	treatment success)		mortality
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure: One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) [18]	representative database of the current HF population (AHF and CHF) in Italy with systematic 1-year follow-up and investigation of clinical profiles, contemporary treatment, outcome rates, and their predictors in both AHF and CHF cohorts	Completed	multicenter (Italy) prospective observational cohort	n= 5610 min. 1 year, up to 2 years	Adults hospitalized for AHF (n= 1855) or receiving outpatient treatment for chronic HF (3755)	Mortality and hospitalization rates at 1 year in AHF vs. CHF pts.	Clinical data and History	<u>1 year</u> mortality hospitalization rates
Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study [19]	to study the risk and predictors of late-onset heart failure (LOHF) and the composite event of LOHF or death after acute myocardial infarction (AMI)	Completed (2004-2013)	Observational study of all patients with acute myocardial infarction entered in the Swedish nationwide registry SWEDEHEART between 2004 and 2013)	n= 150566 5 years	AMI, data entered in SWEDEHEART between 2004 and 2013	LOHF and mortality	Clinical data and History	<u>1 year, 2 year, 5 year</u> LOHF mortality
Prospective Registry of Acute Heart Failure. [20] NCT02444416	to create an observational registry of patients hospitalized for AHF to determine the prevalence of etiologies and the prognostic factors – specifically acute renal failure- of AHF and to establish the optimal initial assessment of patients hospitalized for heart failure	Recruiting (Dec 2014 – June 2019)	Mono-center (University Geneva, Switzerland) prospective observational cohort	n= 1200 2 years	Adults hospitalized for AHF	Prevalence of different clinical AHF presentations and triggers as well as prognostic factors at baseline; rehospitalization and mortality at follow up	Blood sampling/DNA Clinical data and History	<u>1 + 3months, 1 + 2</u> <u>years</u> Rehospitalization Mortality

Epidemiology and Prognostic of the Acute Heart Failure in Northeast of France (EPICAL 2) [21]	to describe the characteristics of the patients affected by acute heart failure and to identify prognostic factors, in particular related to care	Unknown (Jan 2011-May 2017)	multi-center (France) prospective observational cohort	n= 2500 3 years	Adults hospitalized for AHF or developing AHF while hospitalized	Incidence of AHF in a certain region of France	Blood sampling/DNA Urine samples Clinical data and History	Baseline, 6 months, 1,2, 3 years mortality rehospitalization
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients [22] NCT00344513	in an interventional program to improve medical care and education of HF pts. a registry component is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.	Completed (Dec 2002 – June 2005)	prospective interventional non-randomiz ed open-label	n= 50000	Adults hospitalized for HF	Evaluate the number and percentage of eligible patients who are discharged on optimal therapy. Evaluate all HF indicators recommended by JCAHO and CMS	Clinical data and History	Discharge, 3 and 3 months clinical outcome
Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). [23]	survey (by questionnaire) to describe characteristics and management of AHF among various countries, to compare patients with de novo AHF versus patients with a pre-existing episode of AHF, and to describe subpopulations hospitalized in intensive care unit (ICU)versus cardiac care unit (CCU) versus ward	Completed	multi-center, international (666 hospitals, four continents) survey	n= 4953 no scheduled follow up	Adults hospitalized for AHF	Clinical course	Clinical course	none

References AHF

[1] Adams K F, Fonarow G C, Emerman C L, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry ADHERE. Am Heart J 2010;160: 885-92. doi.org/10.1016/j.ahj.2004.08.005 ClinicalTrials.gov Identifier: NCT00366639. Status: Completed.

[2] Hauptman PJ, Goodlin SJ, Lopatin M, et al. Characteristics of patients hospitalized with acute decompensated heart failure who are referred for hospice care. Arch Intern Med. 2007 Oct 8; 167(18):1990-7 *ClinicalTrials.gov Identifier: NCT00366639. Status: Completed.*

[3] Logeart D, Isnard R, Resche-Rigon R. et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. European Journal of Heart Failure (2013) 15, 465–476. doi:10.1093/eurjhf/hfs189 ClinicalTrials.gov Identifier: NCT01080937. Status: Completed.

[4] Zannad F, Mebazaa A, Juillière Y. et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. European Journal of Heart Failure 8 (2006) 697 – 705. doi:10.1016/j.ejheart.2006.01.001. Status: Completed.

[5] Crespo-Leiro M, Anker S D, Maggioni A P., et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure (2016) 18, 613–625. doi:10.1002/ejhf.566. Status Completed.

[6] Nieminen1 M S, Brutsaert D, Dickstein K et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. European Heart Journal (2006) 27, 2725–2736. doi:10.1093/eurheartj/ehl332

[7] Maggioni A P., Dahlström U, Filippatos G., et al. EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure (2010) 12, 1076–1084. doi:10.1093/eurjhf/hfq154

[8] Adnet F, et al. Care Pathways of Acute Heart Failure Patients: Impact on In-hospital Mortality. *ClinicalTrials.gov Identifier: NCT03903198. Status: Completed.*

[9] Sean P. Collins, et al. Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home: The DECIDE Study (DECIDE). *ClinicalTrials.gov Identifier: NCT00911703. Status: Completed.*

[10] Juilliere Y, et al. Permanent Observatory of Heart Failure (ODIN) ClinicalTrials.gov Identifier: NCT01091441 Status:Completed.

[11] Mike Osz, et al. Heart Failure Optimization Study (HF-Opt)ClinicalTrials.gov Identifier: NCT03016754 Status: Recruiting.

[12] Spinar J, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry .Critical Care2011, 15: R291. http://ccforum.com/content/15/6/R291

[13] Chioncel O, Mebazaa A, Harjola V., et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure (2017)19,1242–1254. doi:10.1002/ejhf.890

[14] Teixeira A, Parenica J, Park J, et al. Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. European Journal of Heart Failure (2015)17,1114–1123. doi:10.1002/ejhf.330

[15] Metra M, Mentz R J, Chiswell K et al. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. Eur J Heart Fail 2015;17:109–118. doi:10.1002/ejhf.207

[16] Mebazaa A, Gayat E, Lassus J, et al. GREAT Network. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol 2013; 61:820–829. doi:10.1016/j.jacc.2012.11.054

[17] Shah R, Gayat E, Januzzi JL Jr, et al. GREAT (Global Research on Acute Conditions Team) Network. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol 2014; 63:778–785. doi:10.1016/j.jacc.2013.09.072

[18] Tavazzi L, Senni M, MD; Metra M, et al. Multicenter Prospective Observational Study on Acute and Chronic Heart FailureOne-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry. Circ Heart Fail. 2013;6:473-481. doi: 10.1161/circheartfailure.112.000161

[19] Desta L, Jernberg T, Spaak J, Hofman-Bang C, Persson H. Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study. <u>http://dx.doi.org/10.1016/i.ijcard.2017.05.086</u>

[20] Carballo S. Prospective Registry of Acute Heart Failure. ClinicalTrials.gov identifier: NCT02444416 Status: Recruiting.

[21] Nathalie Thilly. Epidemiology and Prognostic of the Acute Heart Failure (EPICAL2). ClinicalTrials.gov identifier: NCT02880358 Status: Unknown.

[22] GSK Clinical Trials Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). ClinicalTrials.gov identifier: NCT00344513 Status: Completed.

[23] Follath F, Yilmaz M B, Delgado J.F, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med (2011) 37:619–626. doi:10.1007/s00134-010-2113-0

Important recent Acute Coronary Syndrome (ACS) cohorts

Name	Main Objective	Status	Study type	n & observation period	Participant characteristics	Main Outcome	Acute Phenotyping	Follow up
A Chinese Registry to Determine the Genetics Risk Factors and Serumal Biomarkers for Acute Coronary Syndrome (ARSGB-ACS) NCT03752515	to determine genetics risk factors and serial biomarkers of Acute Coronary Syndrome	Recruiting (June 2015 – Oct 2020)	multi-center (China) prospective observational cohort	n=2000 3 years	adults hospitalized for ACS within 48hrs after symptom onset	MACE	within 1 month after recruitmentDemography, Anthrompometry, History, lifestylewithin 3 months after recruitmentBio-sampling for exon sequencing, metabolic profile (Mass Spectrometry, detection of miRNAs expression)	<u>3+ 6 months, 1+2+3</u> <u>years</u> MACE
Biomarkers in Acute Cardiac Care (BACC) NCT02355457	to detect and evaluate new cardiac biomarkers, evaluate and improve ACS risk scores taking into account clinical, gender specific, psycho-social and lifestyle-risk factors, protein patterns and genetic variability in addition to the classical risk factors with respect to the primary endpoint of acute myocardial infarction	Recruiting (July 2013- Dec 2021)	monocentric (UKE, Hamburg, Germany)	n= 3000 4 years	Adults with suspected myocardial infarction who present to the ER	Acute myocardial infarction (AMI) as index event	Clinical data and History Blood sampling (DNA/RAN, cells for genetic, gene expression and proteonomic studies)	<u>1 + 5 month, 2+4 years</u> AMI, mortality, heart failure QoL
French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015 (FASTMI2015)	to identify patients at risk for increased morbidity and mortality after myocardial infarction and could be the basis for the subsequent	Active, not recruiting (Oct 2015- Oct 2027)	multicenter (France) prospective observational cohort	n= 5000 10 yrs	Adults admitted to an coronary ICU for AMI within 48h after symptom onset	All-cause mortality 1 year after hospitalization	Bio-sampling (genetic, serologic, fecal)	<u>Annually up to 10 years</u> Mortality

NCT02566200	realization of specific studies on the optimal therapeutic management of the disease according to the different risk profiles							
Observational Registry on Acute Coronary Syndromes in Campania (Campania RESCA) NCT02650323	to collect data related to management of patients affected by acute coronary syndromes and hospitalized in the Campania Region of Italy	Unknown (march 2016-Marc h 2018)	Monocentric (Federico II University, Naples, Italy) prospective observational cohort	n= 10000 1 year	Adults hospitalized for ACS	1 year survival rate	not specified (registry)	not specified
Registry of Acute Coronary Syndromes in the Lazio Region of Italy (NET-SCA) NCT01216462	to document and evaluate the current presentation and clinical management of Acute Coronary Syndromes (ACS) in in the Lazio region of Italy	Unknown (Jan 2010- Dec 2018)	Multi-center (Lazio, Italy) prospective observational cohort	n= 3000 1 year	All adults hospitalized to CCU in 15 Lazio hospitals	1 year mortality	not specified (registry)	<u>1 year</u> Mortality Hospitalization for ACS, AHF or coronary revascularization
Karolinska Cardiorenal Theme-centre and Stockholm Heartbank (KKT) NCT01204645	to explore the cardiorenal syndrome and provide improved care for the individual patient	Recruiting (May 2010-Jan 2024)	Multi-center (Sweden) prospective observational cohort	n= 10.000 5 years	3 groups of pts: • while hospitalized for ACS • delaye d inclusion at 6/12 months FU after ACS • while admitted for elective coronary angiography	Combined primary endpoint (death, new cardiovasc. event, dialysis)	Clinical data and History Blood sampling Biobanking (DNA, plasma)	<u>1 year</u> Vascular function (arterial stiffness, microcirculation by laser-doppler) <u>5 year</u> renal function decline
The LADIES Acute Coronary Syndromes Study (Ladies ACS) NCT01997307	to investigate the relation between age at menopause and severity of coronary artery disease in menopausal women	Completed (April 2014-Oct 2015)	Monocentric (Italy) prospective observational case-control	n= 675 no follow up scheduled	pts. > 55 years with ACS undergoing coronary angiography; women and men	the severity of coronary artery disease, as appraised by the	Clinical data and History (incl. fertility and menopause)	none

	with acute coronary syndromes and clinical indication to coronary angiography				are enrolled in a 2:1 ratio and stratified to 4 age groups	Gensini score within 1 day	Gensini and SYTAX score to evaluate extent of coronary artery disease	
A Study to Improve Cardiovascular Outcomes in High Risk PatieNts With Acute Coronary Syndrome (ICON1) NCT01933581	to develop a risk score that will inform physicians of the patient's future risk of developing adverse events and provide a better understanding of how to manage older patients with coronary artery disease and also help plan future studies looking at treatment strategies that might be beneficial in improving outcomes	Completed (Oct 2016-Dec 2016)	Monocentric (Newcastle, UK) prospective observational cohort	n= 300 1 year	Pts > 64 yrs admitted with ACS for coronary angiography	occurrence of one or more of death, myocardial infarction, stroke, repeat revascularisation, Bleeding Academic Research Consortium (BARC) defined bleeding (follow-up: 1 YEAR)	Bio-sampling/DNA QoL	<u>1 year</u> Primary outcome QoL
Prospective Registry of Acute Coronary Syndromes in Ferrara (ARYOSTO) NCT02438085	to describe the clinical epidemiology and the current management of acute coronary syndromes (ACS) in the area of Ferrara, Italy	Recruiting (June 2014-June 2020)	Monocentric (University of Ferrara, Italy) prospective observational cohort	n= 5000 5 years	Adults admitted to hospital for ACS	1-year occurrence of cardiac death, myocardial infarction, or cerebrovascular accident	Clinical data and History Acute clinical course Bio-sampling (inflammatory, endothelial, Thrombotic function biomarkers) Plaque morphology in subgroups with comorbidities (diabetes, COPD, CKD, malignancy) vs. no such comorbitities	Annually up to 5 years "Clinical FU" Clinical events QoL
International Survey of Acute Coronary	(1) documentation of the characteristics of all patients presenting	Recruiting (Sep 2010- Dec 2022)	Multi-center, international (Europe)	n= 24.000 1 year	Adults admitted for ACS	All-cause mortality	Clinical data and History	<u>30 days, 6 months, 1</u> <u>year</u>

Syndromes in Transitional Countries (ISACS-TC) NCT01218776	to the ISACS-TC centers with STEMI or NSTEMI (2) documentation of in-hospital outcome, and outcome rates at 6 month and 1 year, (3) documentation of invasive procedures and procedure-associated complications (4) documentation of therapeutic regimens and investigation conformity of treatment with already established guidelines.		prospective observational cohort				Bio-sampling for pharmacokinetic/genetic studies	Clinical outcome (mortality, recurrent ACS, cardiovascular mortality) Adherence to internationally guideline recommended therapies <u>6 months, 1 year</u> Bio-sampling for pharmacokinetic/genetic studies
Inflammation and Acute Coronary Syndromes (SPUM-ACS) NCT01000701	Subprojects (examples)1Discovernovel genomicbiomarkers of ACS inleukocyte subsets bymeans of analyzinggene expressionprofiles and function2Evaluatenovel diagnostic andprognostic biomarkersin soluble form inblood/plasma andurine3Visualize thevulnerable plaqueusing intravascularultrasound/opticalcoherence tomography(IVUS/OCT) andcorrelate with outcomeand biomarkers4Characterizethe effects of	Unknown (Oct 2009-Jan2 019)	Multi-center (Switzerland) prospective observational cohort	n= 4000 1 year	Adults presenting with ACS and 2 control groups (stable CAD, healthy controls, peripheral artery occlusive disease pts)	composite of cardiac death, myocardial infarction or ischemia-driven revascularization	Clinical data and History Bio-sampling (genetics, inflammation)	<u>1 year</u> Composite endpoint Subgroups: Bio-sampling (temporal change in biomarkers) STEMI subgroup: IVUS/OCT (plaque burden)

inflammation on progenitor/stem cell-mediated repair after ACS by means of analyzing gene			
expression profiles and			
function.			

Important recent Stroke cohorts

Name	Main Objective	Status	Study type	N Follow up (FU)	Participant characteristics	Main Outcome	Acute Phenotyping	Follow up Phenotyping
coHort to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in STROKE (HIBISCUSSTROKE) NCT03149705	to identify new markers: biological and imaging, treatment response and prognosis after ischemic stroke.	Recruiting (Oct 2016 – Oct 2026)	monocentric (Lyon, France) prospective observational cohort	n=300 stroke pts. FU: 5 years	adults with MRI confirmed stroke and proximal artery occlusion eligible for revascularization	mRS Score	 Blood samples/DNA MRI infarct size + hemorrhagic transformation 	<u>3 months</u> Blood samples/DNA <u>up to 5 yrs</u> mRS, NIHSS, QoL questionnaire
PROSpective Cohort with Incident Stroke (PROSCIS) [1] NCT01364168	to derive and validate risk scores for vascular endpoints and death following an incident stroke.	Recruiting (Feb 2011 – Dec 2026)	multi-center (LMU Munich and Charité Berlin , Germany) prospective observational cohort	n= 850 stroke pts. FU: 36 months	adults within maximum of 7 days after acute first ever ischemic or hemorrhagic stroke or venous sinus thrombosis	Composite Primary Endpoint (stroke, myocardial infraction, vascular death)	Clinical data and History Pain questionnaire, anthropometry, blood pressure NIHSS, mRS, Barthel, MOCA, MMST, ABI, MRI/CT, ECG, TTE, Blood sampling/ DNA/RNA	<u>3/12/24/36 months</u> Living situation, lifestyle factors, pain questionnaire, medication, mRS, Barthel, cognitive status (TICS-M), depression scale (CES-D)

Cohort for Severe	to investigate	Recruiting	multi-center	n= 2500 stroke	adults within a	mRS after 3	Clinical data and	3 months & 1 year
Ischemic Stroke (SIS) NCT03222024	causes, risk factors, clinical course, management and outcomes of severe ischaemic stroke in a real-world setting	(2017- ?)	(Western China) prospective observational cohort	pts. FU: 1 year	max. of 30 days after acute ischemic stroke of all severities	months	History, acute clinical course mRS, Barthel, MRI/CT Blood sampling/ DNA/RNA	Clinical outcome
The Natural History of Blood-Brain Barrier (BBB) Disruption in Stroke Patients With White Matter Hyperintensities [2] NCT03366129	to follow a cohort of stroke patients with white matter hyperintensities (WMH), using MRI to identify BBB permeability on MRI as a biomarker for disease pathogenesis, activity, and progression.	Recruiting (Sep 2018- Jan 2034)	Multi-center (Columbia and Maryland, USA) prospective observational cohort	n=310 stroke pts FU: 6years	adults with clinical stroke or TIA symptoms admitted to NIH stroke service who have confluent white matter hyperintensities (WMH) on MRI	relationship between the presence of BBB disruption in the NAWM and the progression of WMH over time	MRI	Every three months first year, every 6 month second year, annually till 6 years post inclusion MRI Cognitive/clinical scaling History
Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study NCT02274727	to prospectively evaluate the predictive value of the most promising blood biomarkers to identify treatable stroke etiologies on admission and risk of recurrence	Active, not recruiting (Sep 2014- Oct 2018)	Multi-center, international (Switzerland, USA, Germany, Greece, Spain) prospective observational cohort	n=3000 FU: 1 year	adults with stroke symptoms who had consistent brain imaging within a max. of 24h after onset	recurrent stroke, including fatal stroke	MRI Duplex sonography ECG Blood samples	3 months + 1 year MRI Duplex sonography ECG Blood samples
Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of	to determine the clinical, biological, lesional and pharmacological factors associated with post-stroke	Recruiting (Feb 2010- Dec 2023)	multi-center (France) prospective observational cohort	N=1100 FU: 5 years	Pts. > 40-95 years within 72hrs after acute hemispheric or hemorrhagic	dementia occurrence at 5 years	MRI Blood samples History life style	<u>6 months/ 1year/ 3</u> <u>years/ 5 years</u> MRI Cognitive testing Clinical exam

Dementia or Cognitive Disorders After Stroke (strokedem) [3] NCT01330160	dementia by the long-term follow-up of a stroke patient cohort				stroke without dementia			Activities of daily life
Evaluation of Clinical and Imaging Criteria, and Plasma Biomarkers of Patients Receiving an Endovascular Treatment for an Acute Ischemic Stroke	 Study like register with biomarkers samples for patient experiencing acute ischemic stroke, to assess clinical outcomes and different factors that may affect the clinical outcomes	Recruiting (June 2018-Dec 2022)	multi-center (France) observational (registry) cohort	N= 4000 stroke pts. FU: 3 month	mRS at 3 months	adults with imaging confirmed acute ischemic stroke with large artery occlusion who received thrombectomy	Blood sample MRI	mRS, clinical evaluation (telephone interview)
Cognition and Affect After Stroke: a Prospective Evaluation of Risks (CASPAR) NCT02585349	primary objectives are to identify biomarker-based predictors of post-stroke depression (PSD), post-stroke apathy (PSA), vascular cognitive impairment (VCI), and post-stroke dementia	Active, not recruiting (June 2013- Dec 2018)	monocentric (Maastricht, Netherlands) prospective observational cohort	N= 250 FU: 3 years	Vascular Cognitive Impairment; Post-Stroke Depression; Post Stroke Spathy at 1 year (3 years added later)	adults > 40 yrs with first ever ischemic or hemorrhagic stroke or recurrent stroke if interval to previous stroke is at least 3 yrs with no sequelae	none	Baseline: 10-12 weeks post stroke FU: 6 month, 1 year, 3 years after baseline Blood sample for DNA (ApoE, CLU, PICALM, CR1, ACE, MTHFR) and RNA-Extraction and subsequent analysis of expression of inflammatory and stroke-related genes at the mRNA level Cognition Depression, apathy QoL Barthel

Cytokine Registry Database of Stroke (Ischemic and Hemorrhagic) Patients (CRISP)	creating a database of acute stroke patients containing all pertinent medical demographics and clinical information along with the laboratory data, molecular levels of pertinent cytokines/neural factors	Active, not recruiting (May 2019- Dec 2020)	Monocentric (Albuquerque, USA) Prospective observational cohort	N= 600 stroke pts. vs. patients without stroke FU: 3 years	change of cytokine levels within 24h in the acute stroke phase	Adults within 24h of onset of acute ischemic or hemorrhagic stroke	on admission and 24h later Serum and Urine measurement of cytokines (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001)	follow up for 3 years (not further defined)
Determinants of Dementia After Stroke (DEDEMAS) [4] NCT01334749	to identify predictors of post stroke dementia (PSD) with a particular focus on biological markers (neuroimaging and biochemical) and on interactions between vascular and neurodegenerative mechanisms	Recruiting (April 2011-Augu st 2028)	Multi-center (DZNE at Munich, Charité Berlin , Bonn, Göttingen, Magdeburg, Germany) Prospective Observational Cohort	n= 600 5 years	Dementia occurrence at 5 and 10 years	Adults without dementia but with acute ischemic or hemorrhagic stroke within 72hrs confirmed by imaging	Clinical exam Waist-Hip-Ratio Ankle-Brachial-Index MRI Retinal Imaging Intima-Media-Thickne ss Blood samples Cognitive Testing	6 month & 1,2,3, ,5 years MRI In pts. developing cognitive impairment FDG-PET Amyloid-PET CSF samples
Norwegian Cognitive Impairment After Stroke Study (NorCOAST) [8] NCT02650531	to quantify and measure levels of cognitive impairments in a general Norwegian stroke population and to identify biological and clinical markers associated with prognosis for	Active, not recruiting (May 2015- October 2019)	Multi-center (Norway) Prospective Observational Cohort	n= 816 1,5 years	Cognitive outcome	Adults with acute ischemic or hemorrhagic stroke according to WHO criteria within 7 days after onset	Brain MRI Blood sampling Biobanking (genetics, inflammation) Clinical data and History NIHSS mRS Cognition Physical activity QoL	3 months + 1,5 and 3 Brain MRI Blood sampling Biobanking Clinical data and History NIHSS mRS Cognition Physical activity QoL

	cognitive disorders following incident stroke							
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders	the maintenance and utilization of a repository of samples from patients with cerebrovascular disease and stroke	Recruiting (sep 2016- Sep 2021)	Monocentric (Cedars-Sinai Medical Center, USA) prospective observational	N= 900 FU: 6 months	Change in mRS, NIHSS, Barthel-Index and MOCA	Adults diagnosed with cerebrovascular disease (ischemic stroke, aneurysms, moyamoya disease, arteriovenous malformation, hemorrhagic stroke and surgically treated patients)	Blood samples/ DNA CSF Micodialysis Angiography (DSA)	<u>1, 3 and 6 months:</u> Functional (mRS, Barthel), clinical stroke specific (NIHSS) and cognitive (MOCA) outcome Blood sample / DNA Microdialysis sample CSF <u>6 months</u> Angiography (DSA)
Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance [5] NCT02238470	to evaluate whether Magnetic Resonance (MR) helps in predicting the risk of Intracranial Hemorrhage (ICH-OA) in patients with ischemic stroke who will receive Oral Anticoagulants (OA) for the secondary prevention of stroke	Completed (April 2012 Sep 2017)	Multi-center, international (Italy, France) prospective observational cohort	N= 937 FU: 2 years	Intracranial hemorrhage (every three months until 1 yrs)	Pts older than 64 yrs within acute phase of ischemic stroke or TIA who were not before but will then receive oral anticoagulants for secondary prevention of cardioembolic stroke	history mRS	Within 1 month after stroke: MRI for detection and quantification of leucariosis (FAZEKAS Scale) and microbleedings (BOMBS scale) <u>Every 3 months till</u> <u>1year</u> Clinical events Treatment change
Cerebral microbleeds (CMBs) and intracranial hemorrhage in pts	to establish the value of CMBs and genetic factors in predicting symptomatic ICH following best	Completed (August 2011- October 2017)	Multicenter, international (United Kingdom, Netherlands)	N= 1490 FU: 2 yrs	symptomatic intracranial hemorrhage within 2 years	Adults with ECG-confirmed non-valvular AF and indication for anticoagulation	MRI (including Fazekas scale and MARS-Scale for microbleeds) performd before or a max. of 1 week after	<u>5 montsh, 1 year,</u> <u>2years</u> Clinical events

Anticoagulated for AF after stroke or TIA (CROMIS-2) [6] NCT02513316	practice oral anticoagulation to prevent recurrent ischaemic stroke due to AF					by treating physcician who were admitted to one of the participating hospitals due to ischemic stroke or TIA	initiation of anticoagulation	
Cardiomyocyte Injury following Stroke (CORONA-IS) [7] NCT03892226	to characterize stroke-associated acute myocardial injury (elevated hs-cardiac troponin) using different diagnostic examinations in order get a better understanding of it's underlying pathomechanisms	Recruiting (April 2019- March 2023)	Monocentric (Charité, Berlin, Germany) Prospective observational cohort	N= 300 5 days post admission	Adults with MRI (DWI_)- confirmed acute ischemic stroke within 48hrs after onse, who received repeated measurement of high sensitivity Troponin T (cTn) within 24 hrs	Rate of myocardial edema, fibrosis and left ventricular dysfunction in MRI within five days after admission; rate of acute disturbance of microcirculation in MRI on the 4 th /5 th day after stroke onset; rate of impaired left ventricular function in TTE	Bio-sampling (Biobanking, microRNA) Cardial MRI serial TTE 20 minute Holter ECG with cardial autonomic markers	
Heart and Brain Interfaces in Acute Ischemic Stroke (HEBRAS) [8] NCT02142413	to investigate whether an enhanced diagnostic MRI work-up duration leads to a significant increase in relevant pathologic findings with respect to stroke aetiology as compared to the findings obtained by a routine diagnostic work-up in patients with	Completed (May 2014-Marc h 2018)	Monocentric (Charité, Berlin) Prospective Observational cohort	N= 368 FU: 1 year	Adults within 2 days since onset of acute ischemic stroke confirmed by imaging without history or baseline-ECG-evi dence of atrial fibrillation	Detection rate of findings relevant stroke etiology detected by enhanced diagnostic workup (up to 5 days post stroke) in comparison to findings obtained by clinical routine	Enhanced work up up to 5 days post stroke onset Cardiac MRI MR-angiography brain supplying arteries Prolonged Holter –ECG up to 5 days Heart rate variability Urinary norepinephrine levels	<u>1 year</u> mRS clinical outcome: Mortality, Recurrent stroke , myocardial infarction

	acute ischemic stroke					diagnostic workup* * (stroke unit monitoring, echocardiography, duplex ultrasound brain-supplying arteries, 24h-Holter-ECG)	Troponin T serum levels	
International PFO Consortium	to compare the risk of recurrent stroke and TIA in patients with patent foramen ovale (PFO) and otherwise unexplained stroke who undergo percutaneous device closure (PDC) or receive antithrombotic treatment (ATT)	Recruiting (Dec 2018- Dec 2021)	Multi-center, international (Switzerland, Germany, Belgium, USA, Spain, Italy)	n = 1500 FU: 3 years	Proportion of pts free of any stroke (including fatal stroke) or TIA within 2 years	Adults with TEE confirmed PFO and stroke or TIA within 6 months of stroke onset	none	Outcome after 3 years
Levels of Inflammatory Markers in Treatment of Stroke Study (LIMITS) [11, 12] NCT00579306	to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke	Completed (Feb 2005-July 2012)	multi-center (USA) prospective observational cohort	n= 1244 nested in participants of the phase III interventional Secondary Prevention of Small subcortical Stroke (SPS3) trial (n= 3020) up to 5years	Pts. > 30 yrs with MRI proven typical lacunar stroke who presented with typical clinical lacunar syndromes within d months prior to inclusion; exclusion of macrovascular or cardioembolic etiology	Recurrent stroke	Baseline was not generally restricted to the acute phase (max. <u>6 months post stroke</u>) Demographics and Risk factor history Bio-sampling (inflammatory markers, he primary stroke)	<u>1 year</u> Bio-sampling (ingflammatory markers) <u>up to 5 years</u> clinical outcome (recurrent stroke, cognitive decline)

A Study of the Relationship of Gut Microbial Composition and Stroke Outcome (GEMSTONE) NCT03470506	to investigate the relationship between gut microbial composition and stroke outcome	Active, not recruiting (Dec 2017-July 2022)	Monocentric (University of Virgina, USA) Prospective Observational cohort	n= 300 3 months	Adults hospitalized with ischemic stroke or TIA within 48h of admission	differences in taxonomic make-up and the relative frequency of the gut microbial composition in relation to excellent vs. poor stroke	Stool samples (16s rRNA gene sequencing) Stroke outcome (NIHSS)	3 months Stool samples (16s rRNA gene sequencing) Stroke outcome (NIHSS) Cognitive function
Adipose Tissue Content of Fatty Acids Present in Dairy Fat and Risk of Stroke. The Danish Diet, Cancer and Health (DDCH) Cohort [9] NCT03220568	the association of adipose tissue content of fatty acids, for which dairy products are a major source * with incident total stroke and stroke subtypes will be investigated * 12:0, 14:0, 14:1 cis-9, 15:0, 17:0, 18:1 trans-11 and 18:2 cis-9, trans-11 fatty acids	Completed (Nov 1993-Nov 2009)	multi-center (Aarhus, Denmark) prospective observational case-cohort	n= 5294 (nested in a population -based cohort of n= 57053 FU: baseline till Nov 2009 up to 16 yrs	Danish Cancer, Diet and Health cohort consisted of middle-aged (50-64 yrs) adult Danes from Danish urban areas without history of stroke or cancer at recruitment were followed prospectively. For the case-cohort design all participants with incident stroke (n= 2108) and a random sample without stroke (n= 3186) were included in the current trial	outcome association of adiopose tissue fatty acids with incident stroke and stroke subtypes	Upon inclusion in DDCH (= not in the acute phase of stroke)Diet questionnaireLifestyle questionnaireAnthropometry (BMI etc.)Adipose tissue biopsy (fatty acid composition by gas chromatography)Upon stroke diagnosis Classification of stroke including TOAST	no further follow up after stroke diagnosis
MIIDNOR-TIA- a study of 600 patients with TIA [10] NCT02038725	to investigate stroke risk after TIA in short (1 week) and long term (3 months/1 year), to assess whether the ABCD2 score is an	Completed (July 2014- July 2015)	Multi-center (Norway) prospective observational cohort	n= 577 1 year	Adults hospitalized with probable or possible TIA within 2 weeks after onset* and mRS <4	Number of patients presenting with stroke within 1 week after transient ischemic attack	Clinical Data ABCD2 Blood sampling ECG MRI or CT	<u>31 week, 3 month,</u> <u>1 vear</u> Stroke number TIA number

	adequate tool for predicting stroke risk and explore whether adopting imaging modalities (ultrasound, MRI) and biological markers of blood into a risk score could improve the predictive value of the ABCD2				(* 85 % were evaluated within 24h after onset)		Carotid Doppler or CT angiography	Correlation of ABCD2 with stroke risk
Patient-centered research into outcomes stroke pats. prefer and effectiveness research (PROSPER) NCT02146274	to address existing evidence gaps and develop the requested data on the range of clinical outcomes that may be experienced by stroke survivors	Completed (Nov 2013-dec 2017)	Multi-center (pts from a registry of 75 US-sites followed by researchers from Duke University) USA) prospective observational cohort	n= 2000 stroke survivors prospective observational cohort 1 year	Adult ischemic stroke patients	"Days alive and at home", patient-reporte d outcomes/ Qol and mortality at 1 year	not specified	3 +6 months + 1 year (telephone) Patient reported outcomes/QoL (FSS, PHQ8, MRS, Barthel, EQ-5D, SSQOL-12, IADL) mortality, stroke recurrence
Korean Stroke Cohort for functioning and rehabilitation (KOSCO) [13] NCT03402451	to identify the factors that influence residual disability and long-term quality of life after first ever stroke	Active, not recruiting	Multi-center (Korea) prospective observational cohort	N= 7858 10 year FU	Adults of at least 19 yrs of age with first-ever acute ischemic stroke within 7 days prior to inclusion	Barthel, EQoL-5D, activities of daily living, MMST, Aphasia Screening, mRS, Swallowing, geriatric depression, Fugl-Meyer motor assessment, gait function	Fugl Meyer Motor assessment Gait function Swalloing assessment Aphasia screening	3 + 6 months, than annual up to 10 years See primary outcomes Recurrent stroke mortality
German Stroke Registry- Endovascular Treatment	3 month outcome after endovascular treatment of acute ischemic stroke	Recruiting (June 2015-June 2025)	Multi-center (Germany, including Charité)	n= 2500 3 month	all acute stroke patients with the clinical diagnosis of acute ischemic	mRS at 2 months	Clinical Data and History	<u>3 month</u> (telephone) mRS

NCT03356392			prospective observational cohort		stroke, eligible for IVT and IVT initiated within 4.5 hours after stroke onset, Age >18 years					
Registry Study for the Observation of Patients With ESUS*/Cryptogenic Stroke (Catch-up ESUS registry study) NCT03820375	to provide important data for the detection of an individual approach in ESUS patients based on a structured diagnostic and therapeutic pathway	Recruiting (Jan 2018- Jan 2026)	Monocentric (LMU, Munich, Germany) prospective observational cohort	n= 750 3 years	all adults with ESUS admitted to LMU Munich	Stroke recurrence at 3 years	Clinical History	Data	and	<u>3 years</u> Clinical outcomes: Stroke recurrence, AF detection, other vascular events, predictors of stroke
*ESUS= Embolic Stroke of Undetermined Source										

References Stroke

[1] Liman TG et al.: Prediction of vascular risk after stroke - protocol and pilot data of the Prospective Cohort with Incident Stroke (PROSCIS). Int J Stroke 2013; 8:484-90

[2] Gupta N et al., NIH Natural History of Stroke Investigators: White Matter Hyperintensity-Associated Blood-Brain BarrierDisruption and Vascular Risk Factors. J Stroke Cerebrovsc Dis 2018; 27:466-71

[3] Ponchel A et al.: Influence of medication on fatigue six month after stroke. Stroke Res Treat 2016; doi: 10.1155/2016/2410921

[4] Wollenweber FA et al.: The Determinants of Dementia After Stroke (DEDEMAS) Study: protocol and pilot trial. Int J Stroke 2014; 9:387-92

[5] Martí-Fábgregas J et al., HERO study investigators: MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation. Neurology 2019; doi: 10.1212/WNL.000000000007532

[6] Wilson D et al. al on behalf of the CROMIS-2 collaborators: Cerebral microbleeds and intracranial hemorrhage risk in patients anticogulated for atrila fibrillation after acute ischemic stroke or transient ischemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol 2018; 17:539-47

[7] Hauusler KG et al.. Heart and Brain interfaces in Acute ischemic Stroke (HEBRAS)- rationale and design of a prospective observational cohort study. BMC Neurol 2015; 15:213

[8] Thingstad P et al.: The Norwegina Cognitive impairment after stroke study (Nor-COAST): study protocol of a multicenter, prospective cohort study. BMC Neurol 2018; 18:193

[9] Laursen ASD et al.. Adipose tissue fatty acids present in diary fat and risk of stroke: the Danish Diet, Cancer and Health cohort. Eur J Nutr 2019; 58:529-539

[10] Ildstad F et al.: Stroke risk after transient ischemic attack in a Norwegian prospective cohort. BMC Neurol. 2019; 19:2. doi: 10.1186/s12883-018-1225-y.

[11] Elkind MSV et al.: The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) Study: inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke 2012; 5:117-125

[12] Boehme AK et al: Inflammatory markers and outcomes after lacunar stroke: Levels of Inflammatory Markers in Treatment of Stroke Study. Stroke 2016; 47:659-667

[13] Chang WH et al.: Predictors of functional level and quality of life at 6 months after a first ever stroke: the KOSCO study. J Neurol 2016; 263:1166-77

Important recent Diabetes mellitus cohorts

Name	Main Objective	Status	Study type	N Follow up (FU)	Participant caracteristics	Phenotyping
Metabolic Syndrome Berlin Potsdam (MeSyBePo)	to identify genetic variants of nutritive-metaboli c phenotypes	recruiting 2002-2009	prospective case-control cohort	n= 2600	adults with or without metabolic syndrome or impaired glucose metabolism	 Anthropometry,BMI, Waist-hip-ratio OGTT Lifestyle and medical history Bio-sampling/ genomics
The UK prospective diabetes study (UKPDS)	determine whether: 1. improved blood glucose control and: 2. improved antihypertensive control will prevent complications and reduce the associated morbidity and mortality	Recruitment from 1977-1997	Multi-center, (UK) Prospective randomized intervention trial	N= 5102 9 (3-16) years	25 to 65 years newly diagnosed pats with T2DM (non-insulin-d ependent)	Major clinical events Behavioral History Bio-sampling (LDL, HDL and other biochemical variables)
PPP-Botnia – Prevalence, Prediction and Prevention of Diabetes	impact of a family history of type 2 diabetes on physical fitness, lifestyle factors and diabetes-related metabolic factors	Recruitment from 2004-2008, Follow up start 2011	Multi-center (Finland) Prospective Population-ba sed cohort	n= 5200 6 years	adults 18-78 yrs randomly followed in Western Finland	Baseline • Information on exercise and food habits -psychosocial factors • sleeping pattern • 2 km walking test 6 years FU study more detailed food frequency questionnaire -blood samples during glucose tolerance test for additional hormones (e.g. incretins) • collaborative project with Broad, Fusion and Wellcome Trust currently performing genome-wide sequencing (x6), exome sequencing and 2.5 M Illumina chip on 1500 patients with T2DM and 1500 non-diabetic controls, of whom 2000 come from Finland (Botnia and Fusion) • Illumina Exome chip (every non-synonymous variant observed at frequency >0.1% in populations) will also be used to genotype 5000 T2DM from Botnia & Direva Studies (Direva = Diabetes Register in Vasa region connected with Botnia Study) and 5000 control subjects from the PPP-Botnia (genotypes data will be available for whole PPP-Botnia)

The Madrid Diabetes Study (MADIABETES Study)	epidemiological investigation of diabetes type 2	Recruitment from 2007-2011	Multicentre (Madrid, Spain) prospective observational cohort	n= 3443	age >30 years-old, T2DM outpatients	Baseline + annual FU up to 4 years • History • Eye exam • Physical exam • Biochemical tests
Netherlands Epidemiological Study of Obesity (NEO)	extensive phenotyping to investigate pathways that lead to obesity-related diseases	Recruitment from 2008-2013	Multicenter (Netherlands) Prospective Population-ba sed cohort	n= 6673 longterm	obese (BMI >27) 45-65	Baseline • demography, lifestyle, and medical history • samples of 24-h urine • fasting and postprandial blood plasma and serum (including mixed meal analysis) • DNA/Genomics • extensive physical examination • electrocardiography • spirometry • carotid artery intima-media thickness • MRI in subsets Follow up • • through GP practices in the community • causes of death through national registries • second visit to CRU about to commence
DIACORE (DIAbetes COhoRtE) – a cohort study of patients with diabetes mellitus type 2 prospective cohort (10 years follow-up)	generate hypotheses for innovative strategies in DM2 management by unravelling novel mechanisms of diabetes complications	Start 2010	Multicenter (Germany) Prospective	N= 6000 10 years	Adults of Caucasian ethnicity with prevalent T2DM	 Baseline & bi-annual FU up to 2 years online questionnaire and physical examination for incident micro- and macrovascular DM2 complications, malignancy and hospitalization, primary focus on renal events blood samples for standard laboratory panel and biobanking of aliquots of serum, plasma, urine, mRNA and DNA extended phenotyping, e.g. sleep apnea screening, skin autofluorescence measurement, non-mydriatic retinal photography and non-invasive determination of arterial stiffness
Discover study	aim is to describe the patient characteristics, evolution of disease management patterns and clinical outcomes over 3 years in individuals with	Start 2014	Multicenter international (38 countries, six continents) prospective non-interventi onal study	N= 15000 3 years	Adults with T2DM	 Baseline & FU up to 3 years laboratory tests/ smaller challenge micro-and macrovascular complications questionnaires

	type 2 diabetes mellitus who are initiating a second-line anti-diabetic therapy in real world settings					
Hoorn-Studies	first to identify patients with subclinical T2DM, then use cohort for cardioascular risk assessment.	1989-1991 and 2006-2007	Regional (Hoorn, West-Frieslan d, Netherlands) prospective population-ba sed cohort	N= 5291 10-25 yrs	Adults aged 40-75 yrs from Hoorn	Baseline + FU Glucose metabolism Anthropometry Lipid levels Renal function Blood pressure Family history Behavioral measures Blood sampling/ Biobanking (including DNA) <u>FU subgroup</u> Diabetes complications Cardiac and vascular structure and function (e.g. IMT)
European Prospective Investigation into Cancer and Nutrition (EPIC), including EPIC-Heart/EPIC-C VD and InterAct	Original focus of EPIC was on diet and cancer. EPIC-Heart focusses on coronary mortality. EPIC-CVD extends to cardiovascular morbidity. InterAct focusses on diabetes		Multi-center, international (10 European countries) Population-ba sed cohort	N= 519.978 longterm	Adults aged 25-70	Focus on assessment of diet questionnaires Antropometry Heart rate Blood pressure
DIAB-CORE consortium	to establish a joint pool of population-based data on persons with and without diabetes	1997-2006	pooled cross-sectiona l data from 5 population-ba sed German studies (1997-2006): the Cardiovascular	n= 15071 of which 1287 were diagnosed with T2DM (as reported in 2012*)	Adults with or without T2DM 45-74 yrs of age	Focus on regional differences and factors such as blood pressure control, unemployment, gender in diabetes ** <u>*https://cardiab.biomedcentral.com/articles/10.1186/1475-2840-11-50</u>

Deutsche Diabetes-Studie	evaluation of predictors of diabetes complictions and	recruiting	Disease, Living and Ageing in Halle (CARLA) Study, the Dortmund Health Study, the Heinz Nixdorf Recall Study (HNRS), the Cooperative Health Research in the Region of Augsburg Study (KORA), and the Study of Health in Pomerania (SHIP). Multi-center (Germany) prospective observational	n= 1000 in year 2017 (final recruiting	Adults 18-69 yrs with newly diagnosed T1DM or	** https://www.ncbi.nlm.nih.gov/pubmed/?term=diab-core Baseline, 5 + 10 years • Physical exam • ECG • Body Fat Composition
	investigation on different therapeutical strategies			goal not specified) 10 years	T2DM within 12 months after diagnosis vs. healthy control	 Blood pressure Physical fitness (ergometry) Calorimetry Specialized exam of vascular system, eyes, nerves and kidney Metabolic MRI (liver and muscle)
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with	to assess variability in systolic blood pressure (SBP) and albuminuria (urinary albumin creatinine ratio [UACR]) responses in patients with type 2 diabetes mellitus initiating	2007-2013	multi-center (Netherlands) prospective cohort	n = 1600 15 months	patients with T2DM who started RAAS inhibition	Baseline and FU up to 15 months • Clinical data, Risk factors, diabetes complications • variability in blood pressure • albuminuria * https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969103/

T2DM: A primary care cohort study	renin angiotensin aldosterone system (RAAS) inhibition, and to assess the association of response variability with cardiovascular outcomes *					
Substudy of: Taiwan's National Health Insurance Research Database (NHIRD) for this study. prospective cohort study	Safety and cardiovascular effects of DPP-4i in a nationally representative sample of elderly adults with T2D.	2009 and 2013	Multi-center (Taiwan) prospective observational cohort	N = 58485 2.2 years (mean)	Patients aged ≥65 years with the diagnosis of T2DM registered in the NHIRD	age, sex, monthly income, urbanization level, Charlson Comorbidity Index score, number of outpatient visits to metabolism and endocrinology professionals in the past year, adapted Diabetes Complications Severity Index (aDCSI) score, duration of T2D, other concomitant medications (other antidiabetic drugs, antihypertensive drugs, aspirin, clopidogrel, ticlopidine, nonsteroidal anti-inflammatory drugs, and statins), and baseline major comorbidities
Edinburgh Type 2 Diabetes Study (ET2DS), a prospective cohort study	association of NTproBNP with traditional cardiovascular risk factors and incident cardiovascular events	2006-2007	Regional (Edinburgh, Scotland, UK) prospective cohort	N= 1066 4 years	patients aged 60 to 75 years with T2DM from Edinburgh	 BMI diabetes history, history of CVD social status smoking habits HbA1c, total cholesterol, HDL-cholesterol, eGFR, ACR, SBP, DBP Plasma NT-proBNP CVD events
Observational study from the Swedish National Diabetes Register (S-NDR)	effect of HbA1c and total cholesterol/ HDL-cholesterol ratio (TC/HDL) on risk of CVD.	2000-2007	National (Sweden) prospective cohort	N= 22135 5 years	Adults 30-75 yrs with T2DM registers in the S-NDR	Baseline • BMI • diabetes history, history of CVD • smoking status • HbA1c, total cholesterol, HDL-cholesterol, tracylglycerol • Microalbuminuria • medication Follow up (up to 5 years) • stroke, MI, vascular death • unstable angina, coronary angiography, revascularization, AF https://link.springer.com/article/10.1007%2Fs00125-011-2218-1

Extracted data from the CALIBER programme (CArdiovascular disease research using LInked Bespoke studies and Electronic health Records)	Study associations between T2DM and 12 initial manifestations of cardiovascular disease (stable angina, unstable angina, myocardial infarction, unheralded coronary death, heart failure, transient ischaemic attack, ischaemic stroke, subarachnoid	1997-2010	multicenter (UK) prospective cohort	N= 1.921260/ 34.198 with T2DM 5.5 yrs (median FU)	Registered patients aged ≥30 years old with no history of CV events in England.	 BMI HDL Cholesterol total cholesterol SBP DBP social deprivation smoking status HbA1c Diabetes treatment Cardiovascular preventive treatment
Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes	to quantify the risk of obesity and its associated metabolic dysfunction on the development of cardiovascular events and mortality in patients with type 2 diabetes	1996-2014	prospective cohort	N= 1827 7yrs (median FU)	T2DM Patients from the Secondary Manifestations of ARTerial disease (SMART) cohort study	Baseline • BMI • Waits circumference • anthropometry • standardized estimate of intra-abdominal fat b ultrasound • cardiovascular history, risk factors, medication • physical activity • HbA1c, triglyzerides, HDL, hsCRP Biannually, 7 yrs median stroke, MI, heart failure, vascular death, all-cause death https://www.sciencedirect.com/science/article/pii/S0167527316314280?via%3Dihub
Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular	to evaluate the prognostic value of several measures of glycemic variability for the occurrence of	2004-2008	prospective cohort	N= 654 9,3 yrs (median FU)	T2DM in Rio de Janeiro	 Electrocardiography ischemic stress tests physical examination ankle-brachial index SBP, DBP, microalbuminuria, eGFR, peripheral neuropathy (clinical examination)

complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study	micro- and macrovascular complications, and all-cause mortality in patients with T2DM					fastingHbA1c	athic symptoms by questionnaire glycemia creatinine and lipids
Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients.	investigate the shapes of the associations of SBP and DBP to risk of a composite cardiovascular disease endpoint or total mortality of T2DM patients without previous cardiovascular disease	1999-2008	prospective cohort	N= 34009 Up to 11 yrs	T2DM patients older than 35 years in Sweden	• total, cl (HbA1c), eGFR • smokin	aist circumference holesterol(total, LDL, HDL) triglycerides, glycosylated hemoglobin
Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.	to evaluate the risk of composite CVD including MI, stroke, coronary revascularization, and HF associated with initiation of DPP4i compared to initiation of other diabetes drugs in T2DM patients with and without baseline CVD		prospective cohort	N = 79538 mean 0.7 years for DPP4i and 0.5 years for non-DPP4i initiators; (13297 individuals had FU over 1 year)	patients with T2DM from US commercial insurance claim data with either DPP4 or not	 CVD an Medica healthc Bio-san 	ated comorbidities d other comorbidities itions care utilization factors, npling (serum BUN, creatinine, HbA1c) bidity score
Lower mortality and cardiovascular event rates in patients with Latent Autoimmune Diabetes In Adults (LADA) as	to determine to what extent the prognosis of LADA patients regarding long-term risk of mortality and cardiovascular outcomes is	recruited 1997-2012	retrospective cohort 6,6 yrs	n= 4368 (T2DM n = 3539)	patients with diabetes mellitus (T2DM, LADA, IDD) in southern Denmark	 19 com major r 	I history before diabetes orbidities (from in the Charlson comorbidity index) isk factors for CVD and death pulmonary disease, liver disease, renal disease, and cancer.

compared with type 2 diabetes and insulin deficient diabetes: A cohort study of 4368 patients*	different from that of T2D					*Wod et al. Diabetes Res Clin Pract. 2018
Hypertensive diabetic patients: incidence of cardiovascular and renal outcomes in a historical cohort over 11 years*	identify non-fatal cardiovascular outcomes and renal function impairment in a cohort of hypertensive patients in regular treatment in a reference treatment center	Recruited in 2004 with follow-ups in 2009 and 2015	prospective cohort	n = 139 (T2DM N = 55) Follow up: 11 years	T2DM in hypertension treatment center in midwest Brazil	 gender, race, age, physical activity, alcohol consumption, smoking blood pressure, BMI, glycated hemoglobin, lipid profile diabetes and hypertension diagnosis times, treatment time in specialized non-fatal cardiovascular outcomes renal impairment assessed by creatinine clearance ~Sousa et al. Diabetol Metab Syndr. 2017
TUebinger Lebenstil Interventions Programm (TULIP Diabetes Präventionsstudie)	identification of predictive parameters for the responsiveness to and necessity for lifestyle intervention	2003-2009	interventional (diet and sport)	n= 1635	adults with prediabetes/ T2DM	Baseline, 6 months, 2 years Blood sampling/ DNA OGTT Calorimetry Physical fitness Metabolic MRI/Mr spectroscopy (abdominal and muscle) Magnet Encephalographia (MEG)

Name	Main Objective	Status	Study type	n & observation period	Participant characteristics	Main Outcome	Acute Phenotyping	Follow up
The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. [1]	to characterize the short-term and long-term natural history of AKI, evaluate the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.	ongoing	prospective observational cohort (registry)	n=1100 adults + 100 children 48 moth follow up	adult participants with a broad range of AKI and matched hospitalized participants without AKI; additionally children undergoing cardiac surgery requiring cardiopulmonary bypass	Primary renal outcome: change of renal function, incident of CKD, progression of CKD, development of ESRD, incident or recurrent episodes of AKI; Cardiovascular outcomes: CAD, CHF, cardiac arrhythmias; Cerebrovascular outcomes: stroke, intracranial hemorrhage, carotid endarterectomy; Peripheral arterial disease outcomes: aortic aneurysm, lower extremity arterial revascularization or amputation; Mortality.	Clinical data and history QOL questionnaire, anthropometry, blood pressure, Urinalysis ECG Blood and Urine sampling/ DNA/RNA	4 years
Acute kidney injury increases the risk of end-stage renal disease after cardiac surgery in an Asian population: a prospective cohort study. [2]	to study the the long-term risk of ESRD and mortality in our Asian patients who developed AKI after cardiac surgery	Completed (2008- 2012)	multi-center (Singapore) prospective observational cohort	n= 2666 5 years	adults patients who underwent cardiac surgery	Development of ESRD and mortality	Clinical data and history	<u>5 years</u>

Relevant recent Acute Kidney Injury (AKI) cohorts

Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. [3]	to determine the incidence, risk factors and outcome of acute kidney injury (AKI) in Finnish ICUs	Completed (September 2011-Febru ary 2012)	multi-center (Finnland) prospective observational cohort	n= 2901 3 year	Adults admitted to an ICU with or without AKI	Mortality at 90-days, 1 year and 3 years	Clinical data and history	<u>3 years</u>
Small Acute Increases in Serum Creatinine Are Associated with Decreased Long-Term Survival in the Critically III. [4]	To evaluate the impact of acutebut small changes in SCr (stage 1 AKI) onlong-term survival in a cohort of criticallyill patients admitted to an intensive careunit	Completed (2000- 2009)	Single-center prospective observational cohort	n= 1844 10 years	Adult patients admitted to an ICU with AKI Stage I or without AKI	Mortality during follow up period	Clinical data and history	<u>10 years</u>
Three-year outcomes after acute kidney injury: results of a prospective parallel group cohort study. [5]	to characterise the effect of acute kidney injury (AKI) on long-term changes in renal function in a general hospital population.	Completed (September 2011- October 2012)	Single-centre prospective matched parallel group cohort study	N= 300 3 years	Adult patients who sustained AKI at any point during hospital admission and matched patients without AKI	Renal function and CKD progression, prevalence of proteinuria and albuminuria; Mortality	Clinical data and history	<u>3 years</u>
Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study [6]	To examine the five-year risk of death, myocardial infarction, and stroke after elective cardiac surgery complicated by AKI.	Completed (April 2005- October 2007)	Single-centre prospective cohort study	N= 1030 5 years	Adult patients who underwent acute and elective cardiac surgery	death, myocardial infarction and stroke	Clinical data and history	<u>5 years</u>

References AKI

[1] Go AS, et al., The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol. 2010 Aug 27;11:22. doi: 10.1186/1471-2369-11-22.

[2] Chew et al., Acute kidney injury increases the risk of end-stage renal disease after cardiac surgery in an Asian population: a prospective cohort study. BMC Nephrology 2017; Feb 13;18(1):60. doi: 10.1186/s12882-017-0476-y.

[3] Mildh H. et al., Three-year mortality in 30-day survivors of critical care with acute kidney injury: data from the prospective observational FINNAKI study. Ann Intensive Care 2016; Dec;6(1):118. doi: 10.1186/s13613-016-0218-5. Epub 2016 Nov 29.

[4] Linder et al.: Long-Term Survival after Critical Illness with Acute Kidney Injury. Am J Respir Crit Care Med. 2014 May 1;189(9):1075-81. doi: 10.1164/rccm.201311-2097OC.

[5] Horne et al., Three-year outcomes after acute kidney injury: results of a prospective parallel group cohort study. BMJ Open 2017 Mar 29;7(3):e015316. doi: 10.1136/bmjopen-2016-015316.

[6] Hansen et al., Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study. Crit Care. 2013 Dec 12;17(6):R292. doi: 10.1186/cc13158.

Important other (population-based) cohorts with a primary/significant focus on vascular diseases

Name	Main Objective	Status	Study type	N	Participant	Main Outcome	Follow up Phenotyping
				Follow up (FU)	characteristics		
Second	focus on the	since 1996	Monocentric	N > 10.000	Adults from	Vascular death,	Baseline
Manifestations of	evaluation of		(Utrecht,		18-79 yrs	stroke, myocardial	History and Disk fasters
ARTerial disease	subclinical arterial		Netherlands)		referred to	infarction, aortic	History and Risk factors
(SMART) study [1]	disease (prevalence,				Utrecht	aneurysm rupture.	Anthropometry
	related to future CVD				University	End-stage renal	

KORA (Kooperative Gesundheitsforschung in der Region Augsburg) Project [2]	events, effectiveness of treatment strategies) focus pathogenesis of CVD, Diabetes and lung disease, in particular	Latest studies completed in 2014, currently continued as register for myocardial infarction	prospective observational cohort Regional (Augsburg, Germany) prospective populations-b ased cohort	n= 18.000 local participants of the WHO's MONICA-proje ct (a population- based global study to evaluate trends in CVD) longterm Follow up	Hospital with either atherosclerotic disease (carotid artery stenosis, TIA/ minor stroke, PAD, diabetic foot, abdominal aortic aneurysm, angina pectoris, myocardial infarction) OR for risk factor treatment (diabetes, hypertension etc.) Population-based cohort from the Augsburg region	failure, leg amputation Multiple, e.g. in particular role of psychosocial, socioeconomic, environmental, lifestyle and genetic risk factors	Biosamplimg (Blood plasma, Urine) Exercise challenge (treadmill test) ECG, kidney ultrasound, carotid ultrasound/ IMT Brain MRI substudy (from 2001-2005, ~1200 pts) Follow up Questionnaires Biosamples (Blood, DNA, RNA, Immunophenotyping Urine, saliva, stool) Anthropometry OGTT Lung function ABI
Kopenhagen City Heart Study [3]	describing the distribution of known cardiovascular risk factors as well as the prevalence and incidence of cardio/cerebrovascular disease in a random population sample;	since 1975	Monocentric (Copenhagen, Denmark) Prospective population-ba sed cohort	n= 20.000	Adults form 20-93 yrs from a clearly defined area in central Copenhagen	inclusion in numerous sub-studies	 4 different exam appointments scheduled Bloodsample (Lipds, glucose); pulmonary function Anthropometry, ECG Bio-sampling (micoalbuminuria, lipids, coagulation, DNA)

	forming the background for special studies concerning aetiology, prevention and treatment of various disease entities, especially ischaemic heart disease, stroke and lung diseases; studying genetics, psychosocial factors, arthritis, epilepsy, dementia, excessive alcohol intake and microabluminuria	since 2015	Monocontric		Adulta 45.74		-Echocardiography, PWV, ABI; Bio-sampling (incuding Hba1c, CRp, DNA, mRNA)
Hamburg City Health Study [4, 5]	identifying novel risk factors for major diseases such as coronary artery disease (CAD), atrial fibrillation (AF), heart failure (HF), dementia and stroke. Further interests: prostate and skin cancer, kidney disease, dental disease	since 2015 (recruiting)	Monocentric (UKE, Hamburg, Germany) prospective middle-aged to elderly population-ba sed cohort	n= 45.000 Longterm follow-up	Adults 45-74 years randomly selected from the population of the City of Hamburg		Baseline: allHistoryAnthopometryECG, vacular function, EchocardiographyCarotid and femoral ultrasoundNenous ultrasoundPulmonary functionBio-sampling (Blood and Saliva)Skin ScreeningBaseline: high risk particpantsSleep Apnoea Screening
							Holter ECG Brain MRI Cardio MRI
Lifelines [6]	establish a major biobank available for research on	since 2006	Regional (northern Netherlands)	n= 167.000 30 years	Random sample of the regional population	to provide data from the Biobank for international	Baseline Anthopometry, ECG, Pulmonary function,

	mechanisms of healthy ageing and the development of (chronic) diseases to develop personalized medicine strategies	(recruitmen t completed in 2013)	Prospective population-ba sed cohort		spanning three generations; 67% of the participants have family relation s in the cohort	research projects upon request via a remote workspace system	AGE-Reading, Neurpsychiatric exam (MINI) Cognition (MMSE), Biosampliing (blood , urine) + Genomics (n= 15500 participants), questionnaires (demography socioeconomic, history, medications, physical activity, nutrition, behavioral risk factors, stress)
							<u>Every 1.5 years</u> Questionnaire (demographic Health <u>Every 5 years</u> Study examination
The Rotterdam Study [7]	to evaluate numerous aspects of numerous diseases in the eldery; for cardiovascular disease, the focus is on evaluating lifestyle risk factors, to identify biomarkers and novel mechanisims using genomics, epigenetics and metbolomics, prediction of womens's cv health, high risk predictors of CVD, imaging	since 1990	Regional (Rotterdam, Netherlands) middle-aged to elderly	n= 14.900 (currently expanded by 4000 pesrons aged 40-44 years)	Adults aged 45 or older from the City of Rotterdam	Development of a variety of diseases (coronary artery disease, AHF, ACS, stroke, Parkinson, Alzheimer, depression, anxiety, COPD, diabetes etc.)	Baseline Questionnaires MRI: heart, blood vessels, brain (and eyes, skeleton) Bio-sampling (for metbolomics and genomics) Longterm Follow up Clinical course
The BioImage Study- A clinical Study of Burden of Atherosclerotic Disease in an At-Risk-Population [8,9]	to identify imaging (and other) biomarkers that predict near-term (3-year) atherothrombotic events, with incremental improvement over traditiona Irisk assessment (FraminghamRisk Score)	since 2008 (recruitmen t completed in 2009)	Multi-center (USA) prospective middle-aged to elderly population-ba sed cohort	n= 7687 at least 3 years	men from 55-80 yrs and women from 60-80 yrs from two urban US-region recruited in a 1:1; all without history of CVD; 80% of the population had at least one established CV risk factor	first major CVD events	BaselineAnthropometry, ECG, ABI, Bio-sampling (plasma, serum, RNA, DNA)Baseline : imaging (n= 6104) coronary artery calcification (CAC) score (CT); ultrasound carotid (IMT), abdominal aorta, ABIBaseline: advanced imaging

							carotid plaque MRI (n=525) coronary plaque CTA (n= 380) aortic/carotid inflammation PET-CT (n=180) <u>Follow up (3years +)</u> MACE
Nurses´ Health Study (Cardiovascular Component) NCT00005152	to determine the relationships of hormonal, reproductive, dietary, and lifestyle factors, as well as biochemical and genetic factors, with the subsequent risk of coronary heart disease and other cardiovascular events; recent focus was inflammatory biomarkers, metabolomics, gut microbiota	since 1976 (completion scheduled for May 2019; currently continued as NHS 3 with 280.000 participants)	multi-center (USA) prospective cohort based on a selected female population	n = 121.700 enrollment till April 2019	Adult nurses from 11 federal states	Myocardial infarction, death from coronary artery disease	Baseline questionnaires Bio-sampling (genomics (n= 1186), markers of endothelial inflammation) Follow up cardiovascular events
Multi-Ethnic Study of Atherosclerosis: objectives and design [10]	investigate the prevalence, correlates, and progression of subclinical cardiovascular disease; risk prediction by machine-learning (random survival forests) in conjunction with deep phenotyping [11]	recruited from 2000-2002	multi-center (USA) prospective cohort based on a population of 4 ethnicities	n= 6814 up to 7 yeras	adults aged 45-84 years	vascular events and mortality	Baseline coronary calcium-CT, Cardio-MRI, brachial artery endothelial vasodilataion, carotid IMT, ABI, ECH, Blood sampling (plasma, serum, DNA)
German National Cohort (Gesundheitsstudie Nationale Kohorte) [12]	to investigate the causes (risk factors, lifestyle, environmental, geographic, socioeconomic) for the		mulidentric (Germany) prospective	n= 200.000	adults 20-69, male:female ration 1:1	clinical evnes	Baseline (*marked only in a subset of 40.000 pts) Anthropometry, blood pressure, herat rate, ECG, Echocardigraphy, ABI, pulse wave, longterm ECG*, sleep apnoe screening*

development of major			Diabetes: OGTT, AGE reader*
chronic diseases, including,			Cognition
cardiovascular			Lung function
diseases, and their pre-clinical stages with			Oral health
a focus on risk prediction/biomarkers as well as or functional			Sensory (retinal scan*, visus*, hearing test*, olfactory test)
health impairments			Physical activity
			Bio-sampling (Serum, Plasma, Blood, DNA, RNA, Urine, Saliva, nasal swab, hair)
			History, multiple specific questionnaires
			MRI program (n= 30.000): brain, cardial, whole body
			<u>4-5 years</u>
			as above, but reduced bio-sampling and except for MRI

References population-based cohorts

[1] Simons PCG et al. for SMART study group: Second Manifestations of ARTerial disease (SMART) study: rationale and design.. Eur J Epideiol 1999; 15:773-781

[2] Meisinger C, Peters A, Linseisen J: From the MONICA-project vis KORA to the NAKO-study: Practical Utility of Epidemiological Studies in the Augsburg Region. Gesundheistwesen 2016; 78:84-90

[3] Aguib Y, Suwaidi JA: The Copenhagen City Heart Study (Oesterbroundersoegelsen). Glob Cardiol Sci Pract 2015; 2015:33

[4] http://hchs.hamburg/

[5] Bohnen S et al.: Cardiovascular magnetic resonance imaging in the prospective, populations-based, Hambug City Health cohort study: objectives and design. J Cardiovasx Mag Res 2018; 20:68

[6] Scholten S et al.: Cohort profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 2015; 44:1172-1180

[7] Ikram MA et al.: The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol 2017; 9:807-850

[8] Muntendam P et al. for the High-Risk-Plaque Initiative: The BioImage study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease- stdesign and objectives. A Heart J 2010; 160:49-57

[9] Baber U et al.: Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerois in asymptomatic adults. The BioImage Study. Am Coll Cardiol 2015;65:1065–74

[10] Bild DE et al.: Multi-Ethnic study of Atherosclerosis: objectives and design. A J Epidemiol 2002; 156:871-881

[11] Ambale-Venkatesh B et al.: Cardiovascular event prediction by machine learning. The Multi-Ethic Study of Atherosclerosis. Circ Res 2017; 121:1092-11

[12] German National Cohort (GNC) Consortium: The German National Cohort: aims, study design and organization. Eur J Epidemiol 2014; 19:371-382